🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Lakefront Biotherapeutics NV (AMS:LKFT)
Netherlands flag Netherlands · Delayed Price · Currency is EUR
31.32
-0.14 (-0.45%)
Nov 18, 2026, 5:39 PM CET
← View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

Gamgertamig data support immune-reset potential, with ITP and wAIHA registrational studies planned for 2027 and broader basket expansion in H1 2027. €2.2bn cash and Gilead cost-sharing provide development and investment flexibility.

Shan Hama
Analyst, Jefferies

Everyone, welcome to the Jefferies Global Healthcare Conference. I am Shan Hama from the European Pharma and Biotech team here at Jefferies. I am very lucky to be joined by Lakefront Biotherapeutics. We have the CEO, Henry Gosebruch, we have the CFO, Aaron Cox, and we have the CMO, Eric Hedrick. Thank you very much for joining us. Perhaps with some introductory questions. It has been a very transformative last 12 months for the company. For investors who may not have followed Lakefront, how would you compare the company that exists today versus a couple of years ago?

Henry Gosebruch
CEO, Lakefront

Great. First of all, we are delighted to be here. Thanks for having us back. Good to be back at Jefferies London. We are just a completely different company than we were a year ago. A year ago, I was here representing Galapagos. We, at that point, had a pipeline of cell therapy programs that was burning about 300 million a year. We did not believe that that pipeline had any commercial future.

We had an existing relationship with Gilead, and we were really just beginning to start the process of speaking with the unions and works councils on the potential wind-down of cell therapy. That is where we were last year. Now we are back. We are Lakefront. We have an exciting portfolio of T-cell engagers. We have a new senior team. We have managed the cash very aggressively and positively.

It is going to be an exciting six months of additional data releases and moving forward on our clinical programs. The cell therapy programs have been substantially wound down at this point. So, very different picture than a year ago.

Shan Hama
Analyst, Jefferies

Thanks very much. Let us just jump straight into gamgertamig, which is arguably your most important asset. In June, of course, Lakefront and Gilead completed the acquisition of Ouro Medicines, and you have this BCMAx CD3 gamgertamig in your portfolio. Having now had the opportunity to review the data, sir, and integrate the team, what has increased your conviction since signing this deal?

Henry Gosebruch
CEO, Lakefront

We are very pleased with how the clinical data is performing. We had seen a lot of clinical data when we did the deal. That was both investigator-initiated studies as well as early data from the company-sponsored studies. We were accepted at ASH to have a poster presentation, and we just press released the ASH abstract, which reflected data from over the summer.

But of course, since then, the data has continued to mature further. It is coming in exactly as we hoped it would, with a very attractive immune reset profile, and we think a very significant step forward for patients in these diseases. As I said, we are excited to expand the program and try to bring that to patients as soon as possible.

Shan Hama
Analyst, Jefferies

Thank you very much. If we actually just touch on the ASH abstract, what should investors keep in mind when looking at the ASH abstract, and what could change, other than maturity, of course, and perhaps increased follow-up when looking at the actual data at ASH?

Eric Hedrick
Chief Medical Officer, Lakefront

Yeah, I think when looking at the abstract itself and then the presentation at ASH, again, as Henry mentioned, this is an immune reset therapy. Sort of inherent to that sort of therapy, you need a couple of steps to actually fulfill the criteria for having an immune reset effect or response. The first step is that your molecule needs to provide sufficient depletion of B cells and plasma cells.

We have established now over a number of different doses that we can have that effect. During that period of immune cell depletion, we have seen very robust responses, remissions happen almost uniformly. So these are all necessary steps, but ultimately, what you need to see is with longer follow-up, and particularly after the immune system reconstitutes, that hopefully the remissions will remain.

There is a lot of sort of, I think, different versions of immune reset being floated out there now. That would be one clinical definition of relevance, that you have a sustained remission following B cell and plasma cell reconstitution.

In the ASH abstract, you see that the majority of patients who were able to achieve a response during the period of immune cell depletion retain that response even when the immune system reconstitutes. So, we feel as though with more mature data, we are sort of checking the boxes in terms of describing an immune reset type of effect. Like Henry mentioned, so far with the maturity of this company-sponsored trial data, we are happy with what we are seeing.

Shan Hama
Analyst, Jefferies

Thank you very much. I would argue that autoimmune diseases still remains a pretty white space. There's still a lot to do in that area. What is it about BCMAx CD3 targeting that you believe is an attractive modality for autoimmune diseases?

Eric Hedrick
Chief Medical Officer, Lakefront

Yeah. We were attracted to BCMA as a target because of some sort of transformation in recent understanding of BCMA. BCMA historically was thought to be restricted to plasma cells, and hence, led to its use approval in the setting of multiple myeloma. I think more recently, we've realized that BCMA can be expressed further down in the B cell maturation lineage, down to the naive B cell stage.

What we see with our BCMA-directed T-cell engager is actually depletion not only of plasma cells, but B cells as well. Obviously, for diseases where autoantibodies are an important pathogenic factor, you want to be able to eliminate plasma cell activity. That's where the autoantibodies are stemming from. That's what interested us in BCMA as a target.

CD19, which is the other target within the immune reset field, has some value as well, almost certainly. But what attracted us to BCMA was the fact that you were able to deplete both cell populations that were involved in autoantibody-associated immune diseases.

Henry Gosebruch
CEO, Lakefront

Yeah, and to your point, I mean, there's a lot still to do in autoimmune diseases. We were attracted to this program, so we think it has potential in maybe as many as 20 diseases, with a really unique profile and an opportunity to really meaningfully move the standard of care for patients in those diseases. So, we absolutely agree there's a lot of white space in autoimmune diseases.

Shan Hama
Analyst, Jefferies

Yeah, and just off the back of that, actually, is there potential for gamgertamig to be more of a platform asset as opposed to just for wAIHA and ITP?

Henry Gosebruch
CEO, Lakefront

Absolutely. You will see us, as we publicly stated, you see us expand pretty rapidly this upcoming year. We have announced two basket studies of a broad set of diseases, both in neuro indications and endocrine indications. And there will be additional opportunities down the road as well. Yes, we very much see this as a program that can have a very expanded clinical program.

But what also is very attractive is that these studies are pretty small, all things considered. The effect is so significant, we really do not need many patients to prove that there is utility in a number of different diseases. We like that from a capital perspective. They are very efficient, they are quick to market, and those are all attractive features as well.

Shan Hama
Analyst, Jefferies

Very clear. When we think about the current autoimmune treatment paradigm, of course, you have CD19 CAR-Ts, you have CD20s, but perhaps they are not really addressing the sort of key underlying disease for these patients. Where do you think the BCMA targeting ultimately sits within that treatment paradigm when thinking of it more commercially?

Eric Hedrick
Chief Medical Officer, Lakefront

Yeah, I would say the hope in general, if you look at, take ITP, which is probably our lead indication at this point, there are lots of treatments out there. They are effective in some way or another. What the field lacks is a treatment that actually eliminates or eradicates the disease activity, right?

ITP is a good example of a chronic autoimmune disease where there are effective drugs of some sort, but they are all chronically administered. The idea here is to give a short course limited treatment and actually induce a treatment-free remission, and that idea of a treatment-free remission with durability that is sufficiently long is something that is missing from the arsenal of treatments for autoimmune disease right now, and that is really the aim of a treatment like gamgertamig.

Shan Hama
Analyst, Jefferies

Understood. Thanks very much for that. You have indicated that registrational development could begin as early as 2027 in both ITP and wAIHA. What remaining questions do you still need answered before fully committing to those studies and actually getting them ahead?

Eric Hedrick
Chief Medical Officer, Lakefront

I would say we are a long way towards planning and hopefully initiating those studies next year. We will obviously have to have discussions with regulators around the design of those trials, which we intend on doing. I would say that a lot of pieces of the puzzle in terms of what you need to design the phase III are already in place.

We feel that we are in a good place with the treatment regimen, with the dose, with understanding the level of activity we are seeing in relation to the primary endpoint of those studies. One, I think, factor that we will follow closely along with these remissions is the durability issue of these remissions. We do not think that is a limitation, though. If that is a not yet solved question, that really does not factor into the phase III designs, in our interpretation of those designs.

So obviously, with more follow-up, we will be more interested in seeing the true durability of these remissions. But that is different than knowing what we need to have in place to go into phase III, and we think that we are basically there.

Shan Hama
Analyst, Jefferies

Understood. The other interesting thing, and the thing we get a few questions about from investors is, I mean, shortly after the Ouro transaction, you had UCB acquiring Candid Therapeutics. That sort of effectively endorsed the BCMA direct depletion as an autoimmune strategy as well. Has anything you have seen from competitive programs reinforced or changed your view on the opportunity?

Henry Gosebruch
CEO, Lakefront

No, is really the short answer. I mean, we did some pretty in-depth diligence on all the other programs, not just BCMA, but some of the other approaches. Again, it's playing out the way we had anticipated. What we really liked about the Ouro programs that we acquired is that they were first in class with a multiple-year advantage in those diseases.

Some of the other sponsors have approached more competitive diseases with more existing options. But the Ouro programs are really focused on places where the competitive intensity is less and where there's just a very exquisite relationship between B cell depletion and patient impact ultimately. None of that has changed. Look, we would not be surprised to see more competition coming into it, and we welcome that.

I think we're quite well-positioned, having already established a good dosing regimen, safety, and of course, demonstrated now clinical efficacy and safety for patients. So, I think we're far ahead of some of those new folks coming in. But look, it's going to be an attractive space, and we welcome competition.

Shan Hama
Analyst, Jefferies

Got it. You also have three preclinical autoimmune programs that came with the Ouro acquisition. What are the expected development candidate and IND timelines? Is there anything you can reveal to us or tell us about the thinking regarding those preclinical assets?

Henry Gosebruch
CEO, Lakefront

We're quite excited about the preclinical programs, since they represent really a good mix of some known targets and some more novel approaches. But at this point, we'd like to really keep the focus on gamgertamig. That is the furthest advanced program, as we talked about, ready to go into registration studies. I think there'll be a point next year where we'll share a little bit more about the preclinical programs, and we'll make that a part of our story. But I think at this point, there's a lot to talk about with gamgertamig, and we'd like to keep the focus on that.

Shan Hama
Analyst, Jefferies

Very clear. And of course, you have a very important strategic partnership with Gilead. How does that relationship work between Lakefront and Gilead, particularly as it comes to the Ouro programs?

Henry Gosebruch
CEO, Lakefront

One of the big focus areas of this past year was really to change that relationship. Gilead is a valued partner, but Gilead had specific opt-in rights where they could, at a sort of a discounted value, opt into any POC program that we as a company have or would acquire or would build. So, obviously, that was a challenging situation to be in when you're starting over and you're trying to bring in a new portfolio.

So, when we did the Ouro deal, we, in parallel, negotiated with Gilead, and we came to a really good arrangement where they, instead of paying us $150 million, they paid for half the transaction. They're paying for half the R&D going into it. They will be the commercialization partner, so we avoid any medical affairs, marketing, commercial investments.

We are just responsible in partnership with them, in a 50/50 partnership, to pay for the R&D, and then we get a nice royalty on the back end. So we're very happy with how we moved that. Important to understand is on the preclinical programs, we actually agreed on a 50/50 profit split all the way through to commercialization.

And certainly, that would be more the model of any future deal. If there was another deal, that would be more the model we would aim to achieve. Again, we're happy. They're a valued partner. We look forward to seeing what they can do once the clinical program is expanded and we're in registration studies in terms of accelerating the program and just putting their muscle and their firepower behind it. So we're pleased with how that's been reshaped over the last year.

Shan Hama
Analyst, Jefferies

Understood. If we speak a little bit about your financial position, you've guided to roughly around EUR 2 billion of year-end cash, and that leaves at least EUR 1.6 billion remaining even after funding the portfolio through first approval, which is a pretty unique position for a company like yourselves to be in, I would argue. How does that change the strategic options available for Lakefront and potential investment strategies to continue growing the company?

Aaron Cox
CFO, Lakefront

Yeah, we're certainly in a unique position as a biotech with presently EUR 2.2 billion of cash on the balance sheet. Importantly, we also have a number of inflows coming in, which is also unique to biotech, and those comprise EUR 20 million-EUR 25 million annually in royalties.

We have about EUR 125 million in aggregate of cash tax refunds that'll be coming in over the next five years, and obviously, interest income coming off of that EUR 2.2 billion. With all of that, it provides great strategic flexibility in terms of how do we want to deploy that capital? Do we want to sit on the sidelines and just fund our current portfolio? Do we want to go after potential new acquisitions, whether in partnership with Gilead or on our own?

Importantly, with this Ouro transaction, we did carve out EUR 500 million of capital where we can do transactions independent of Gilead, and also, a part of that EUR 500 million, we have a $150 million sub-limit to return capital to shareholders, which we've done over the last several months. We completed a EUR 50 million buyback in October, and yesterday, we launched another EUR 50 million buyback. But we certainly are in a great position with the cash on the balance sheet and enough cash to go out and do something outside of our current portfolio with that EUR 1.6 billion that you mentioned.

Shan Hama
Analyst, Jefferies

Understood. Just on your last point, actually, what is Lakefront and/or Gilead really looking for in future assets outside of gamgertamig? What therapeutic areas excite you? What modalities?

Henry Gosebruch
CEO, Lakefront

Yeah, look, we have a wide aperture to some degree, but what we're looking for is similar to the Ouro portfolio. We want to look for very clear clinical proof of concept, so a significant amount of patient-level efficacy and safety data, and that's what we had in the Ouro portfolio. Some of the other things I mentioned along the way already, having an ability to very time and capital efficiently move programs forward, so we're not looking for very large programs with lots of development dollars needed.

That's kind of the history we came from, and we don't want to do that again. So these need to be either rare or underappreciated areas where, again, you can very quickly come to a clinical program that can move you forward. Certainly, autoimmune indications are top of the list given the portfolio we've established, but we're looking broadly.

Now, that all being said, we love our current portfolio. We've got a lot to do, not just on gamgertamig, but the preclinical program. Look, we're in no rush to rush to the second deal, and we'll see what opportunities present themselves. But we'll be very, very financially disciplined as we were on the first deal, and that will absolutely be another key guideline for us as we look at additional deals.

Shan Hama
Analyst, Jefferies

That's very, very clear. Then when we think about the next couple of years, should we expect cash burn to sort of inflect higher, as you put gamgertamig into registrational development? Or is the sort of current collaboration structure with Gilead strong enough to actually lower the costs associated with certain programs?

Aaron Cox
CFO, Lakefront

Yeah. So, how it's structured is, Gilead will We will fund anything preregistrational, and then we'll split 50/50 costs with Gilead for registrational trials. So, obviously, the cost to both sides will be less than if we were individually funding them. We haven't given specific guidance on a year-by-year basis, but we did give that EUR 1.6 billion remaining after funding the full potential of gamgertamig and our preclinical portfolio. That's not just current indications. That could fund additional indications beyond the ones that we've already said publicly.

Shan Hama
Analyst, Jefferies

That's very, very clear. Then perhaps if we think a little bit about the key catalysts to look out for over the next couple of years, what should investors really be focusing on for Lakefront Biotherapeutics, in terms of its value proposition?

Henry Gosebruch
CEO, Lakefront

Yeah. As I said, we were very pleased to have been accepted by ASH, and that acceptance press release unveiled for the first time the tip of the iceberg of the clinical data that we got so excited about. That was the starting point. Of course, there'll be more detail at the actual ASH Congress, more mature data, bigger number of patients, et cetera.

That'll come up in about a month. Then early next year, again, as I said, you'll see us expanding the clinical program and starting these basket studies. We do have a significant amount of investigator-initiated data that we've seen, but that we don't have publication rights. We are aware of what these investigators are doing from a publication perspective, so you'll see some of that next year as well, and that'll further add to the body of clinical evidence.

Really, with the ASH abstract press release, we're entering a period of pretty heavy clinical data and then clinical execution milestones over the next six to nine months. Then the last piece will be these preclinical programs that'll come in at some point next year. We'll talk about those a little bit as well.

Shan Hama
Analyst, Jefferies

Understood. Actually, just on those basket studies, it's myositis, Sjögren's, and pemphigus, if I remember correctly.

Henry Gosebruch
CEO, Lakefront

That is a current basket study that's ongoing. I'm really talking more about new basket studies we'll initiate in the first half of next year in neurologic diseases as well as endocrine diseases. They will significantly expand the clinical program for gamgertamig and allow us to pursue many of these additional indications in a very capital-effective way.

Then be in a position in the not-too-distant future to add additional registration programs to our broader program, which, of course, is very important, just given what this medicine has the potential of doing. It'll also give us access to additional milestones from Gilead, and then, of course, a bigger pie of royalty income down the road. It's something we're very focused on.

Shan Hama
Analyst, Jefferies

Of those current indications within the current basket study, is there one that you see the strongest rationale for with respect to BCMA?

Eric Hedrick
Chief Medical Officer, Lakefront

Yeah, I think it's a little bit difficult to answer that question. I think one of the things that we're facing is sort of the limits of our understanding of the real immunology behind some of these diseases. Again, this is a place where we feel like we have an advantage in having a BCMA-directed molecule, because if it's purely autoantibody production by long-lived plasma cells, that should be addressed with BCMA.

If it's more B cell, T-cell interactions during the B cell maturation phase that are in operation, then BCMA should address that cell population as well. Yeah, and honestly, one of the best ways to sort out the immunology of these diseases is treating patients with gamgertamig and seeing what their responses look like and what their durability look like. But that's something that we'll sort of establish along the way as we do clinical trials.

Henry Gosebruch
CEO, Lakefront

Yeah, and that's again the elegance with these basket studies, where we can simultaneously really have a large number of additional indications that we can assess. Given the profound impact that this program has on B cell depletion and ultimately patients and their quality of life, it's not going to take many patients to really see efficacy in additional indications. So, high single digit, low double-digit number maybe. So again, it's a very effective way to really answer that question, not just theoretically, but frankly, clinically. So, we're quite delighted to start those studies early next year.

Shan Hama
Analyst, Jefferies

Understood. Any questions from the audience? No? Thank you very much for joining us. Thank you.

Henry Gosebruch
CEO, Lakefront

Very good. Thanks, everyone.